Haemostatic Drugs

A critical appraisal

  • M. Verstraete

Table of contents

  1. Front Matter
    Pages I-X
  2. M. Verstraete
    Pages 1-7
  3. M. Verstraete
    Pages 8-10
  4. M. Verstraete
    Pages 26-37
  5. M. Verstraete
    Pages 39-44
  6. M. Verstraete
    Pages 54-57
  7. G. Derouaux
    Pages 67-67
  8. P. de Nicola
    Pages 94-99
  9. M. Verstraete
    Pages 108-117
  10. M. Verstraete
    Pages 127-131
  11. M. Verstraete
    Pages 132-139
  12. M. Verstraete
    Pages 142-144
  13. Back Matter
    Pages 154-155

About this book


clinical efficacy of haemostatic agents had to be published work and had to fulftl most of the following minimum requirements: (1) Quantitation ofthe measured blood loss was required, and not merely a clinical impression of the amount of blood lost, if the document pertained to a planned but «open» clinical trial. (2) Only double-blind trials with random allocation of the placebo and experimental drug to preselected patients were considered suitable for discussion, if the blood loss had not been quantitated in a prospective trial. (3) Defmition and appropriate selection of patients admitted to the trial: all inclusion and exclusion criteria used to select patients had to be mentioned in detail. (4) Once included in the trial, patients could be withdrawn only on the basis of strict criteria for withdrawal which had been defined in advance. (5) A double-blind trial had to be continued for an adequate length of time if the haemostatic agent was being assessed in the prevention of bleeding in patients with a long lasting bleeding disorder . (6) A clear and detailed statistical analysis of the results was required. Moreover, a clear distinction between the therapeutic and prophylactic value of the haemostatic agent had to be made and applied separately to the group of patients without any major basic disorder and those with a bleeding disorder e.g. : chronic thrombocytopenia, haemophilia, Rendu-Osler telangiectasia ... General statements not substantiated by experimental data, even when issued by well-known authorities, were not considered a reasonable basis for discussion.


alcohol blood clinical trial drug drugs patients prevention tissue

Authors and affiliations

  • M. Verstraete
    • 1
  1. 1.Department of Medical ResearchUniversity of LeuvenBelgium

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media B.V. 1977
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-90-247-2020-0
  • Online ISBN 978-94-010-1106-8
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology